King Aims To File New Acurox NDA In Early 2011
Executive Summary
King Pharmaceuticals expects to file a new drug application in early 2011 for its pain drug Acurox, excluding niacin as a potential abuse deterrent, execs told investors during a first quarter earnings call May 5
You may also be interested in...
Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility
King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.
Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility
King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.
Acurox Drops Niacin, But King And Acura Need New Study For Reformulation
Firms will submit NDA for a revised version of their oxycodone formulation Acurox that offers impediments to abuse by snorting or injection but does not contain niacin, which FDA says is ineffective at preventing oral abuse.